Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.

@article{Yamada2013LeucovorinFA,
  title={Leucovorin, fluorouracil, and oxaliplatin plus bevacizumab versus S-1 and oxaliplatin plus bevacizumab in patients with metastatic colorectal cancer (SOFT): an open-label, non-inferiority, randomised phase 3 trial.},
  author={Yasuhide Yamada and Daisuke Takahari and Hiroshi Matsumoto and Hideo Baba and Masato Nakamura and Kazuhiro Yoshida and Motoki Yoshida and Shigeyoshi Iwamoto and Ken Shimada and Yoshito Komatsu and Yasutsuna Sasaki and Taroh H Satoh and Keiichi Takahashi and Hideyuki Mishima and Kei Muro and Masahiko Watanabe and Yuh Sakata and Satoshi Morita and Yasuhiro Shimada and Kenichi Sugihara},
  journal={The Lancet. Oncology},
  year={2013},
  volume={14 13},
  pages={1278-86}
}
BACKGROUND Studies done in Asia have shown that a regimen of S-1 plus oxaliplatin (SOX) has promising efficacy and safety in patients with metastatic colorectal cancer. We aimed to establish whether SOX plus bevacizumab is non-inferior to mFOLFOX6 (modified regimen of leucovorin, fluorouracil, and oxaliplatin) plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer. METHODS We undertook an open-label, non-inferiority, randomised phase 3 trial in 82 sites in Japan. We… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 19 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 72 extracted citations

Similar Papers

Loading similar papers…